This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Digging into the data presented at AHA 2024 on nexiguran ziclumeran and Nucresiran in patients with ATTR-CM
Ticker(s): NTLA, ALNYWho's the expert?
- Director, Heart & Vascular Center
- 20-24 patients with ATTR amyloidosis
- Aware of PRONTO study (investigational drug phase II), drug trial vutrisiran, isatuximab, epidemiology study with patrisiran, and a PET/MR study for diagnosis.
Interview Goalto discuss the current treatment landscape and the potential of nexiguran ziclumeran (nex-z, NTLA-2001), a CRISPR-based gene editing therapy and Nucresiran (ALN-TTRsc04), an RNAi therapeutic which are being developed for the treatment of ATTR amyloidosis and cardiac disease progression.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
